Sol-Gel Technologies logo

Sol-Gel TechnologiesNASDAQ: SLGL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

01 February 2018

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$15.49 M
-92%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
27%vs. sector
-97%vs. 3y high
41%vs. sector

Price

regular market | Mon, 04 Nov 2024 14:30:00 GMT
$0.56+$0.05(+9.00%)

Dividend

No data over the past 3 years
$5.43 M$2.69 M
$5.43 M$1.98 M

Analysts recommendations

Institutional Ownership

SLGL Latest News

All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
zacks.com27 August 2024 Sentiment: POSITIVE

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
globenewswire.com17 August 2024 Sentiment: POSITIVE

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
zacks.com16 August 2024 Sentiment: POSITIVE

Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
zacks.com20 May 2024 Sentiment: NEGATIVE

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
globenewswire.com16 May 2024 Sentiment: POSITIVE

NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company specializing in treatments for severe skin conditions, is currently conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome. In addition to their two approved large-category dermatology products, TWYNEO® and EPSOLAY®, Sol-Gel announced today that they have entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. Ltd. in China for the commercialization of TWYNEO for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.

Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research10 August 2023 Sentiment: NEGATIVE

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.

What type of business is Sol-Gel Technologies?

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

What sector is Sol-Gel Technologies in?

Sol-Gel Technologies is in the Healthcare sector

What industry is Sol-Gel Technologies in?

Sol-Gel Technologies is in the Biotechnology industry

What country is Sol-Gel Technologies from?

Sol-Gel Technologies is headquartered in Israel

When did Sol-Gel Technologies go public?

Sol-Gel Technologies initial public offering (IPO) was on 01 February 2018

What is Sol-Gel Technologies website?

https://www.sol-gel.com

Is Sol-Gel Technologies in the S&P 500?

No, Sol-Gel Technologies is not included in the S&P 500 index

Is Sol-Gel Technologies in the NASDAQ 100?

No, Sol-Gel Technologies is not included in the NASDAQ 100 index

Is Sol-Gel Technologies in the Dow Jones?

No, Sol-Gel Technologies is not included in the Dow Jones index

When was Sol-Gel Technologies the previous earnings report?

No data

When does Sol-Gel Technologies earnings report?

The next expected earnings date for Sol-Gel Technologies is 08 November 2024